Morningstar

MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that ...
Morningstar

Ferring Demonstrates Effectiveness of a Treat-to-Target Approach in Mild-to-Moderate Ulcerative Colitis in First Major Study

Ferring Pharmaceuticals today announces results from the OPTIMISE study showing the first real-world evidence of the effectiveness of a treat-to-target (T2T) approach based on faecal calprotectin (FC) ...
clinicaladvisor.com

Treatment of Ulcerative Colitis: Biologics and 5-Aminosalicylic Acid

Credit: Getty Images. Medications for ulcerative colitis include first-line therapy 5-ASA for mild cases as well as immune system–altering biologics for more severe cases. The initial treatment with ...
Healio

VIDEO: ‘Exciting time’ in treatment of ulcerative colitis

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. This is an exciting time to think about ...